GlycoMimetics (GLYC) Competitors $0.25 +0.01 (+5.20%) (As of 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GLYC vs. GALT, MURA, CNTB, IOBT, IVVD, DYAI, STTK, ALVR, SPRO, and CELUShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Galectin Therapeutics (GALT), Mural Oncology (MURA), Connect Biopharma (CNTB), IO Biotech (IOBT), Invivyd (IVVD), Dyadic International (DYAI), Shattuck Labs (STTK), AlloVir (ALVR), Spero Therapeutics (SPRO), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Galectin Therapeutics Mural Oncology Connect Biopharma IO Biotech Invivyd Dyadic International Shattuck Labs AlloVir Spero Therapeutics Celularity Galectin Therapeutics (NASDAQ:GALT) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations. Which has more risk & volatility, GALT or GLYC? Galectin Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Do insiders and institutionals have more ownership in GALT or GLYC? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by insiders. Comparatively, 8.7% of GlycoMimetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, GALT or GLYC? GlycoMimetics has higher revenue and earnings than Galectin Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.73-1.51GlycoMimetics$10K1,603.72-$36.90MN/AN/A Does the media refer more to GALT or GLYC? In the previous week, Galectin Therapeutics had 13 more articles in the media than GlycoMimetics. MarketBeat recorded 17 mentions for Galectin Therapeutics and 4 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.59 beat Galectin Therapeutics' score of 0.40 indicating that GlycoMimetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GlycoMimetics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer GALT or GLYC? Galectin Therapeutics received 32 more outperform votes than GlycoMimetics when rated by MarketBeat users. However, 59.32% of users gave GlycoMimetics an outperform vote while only 59.22% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.22% Underperform Votes23940.78% GlycoMimeticsOutperform Votes31559.32% Underperform Votes21640.68% Is GALT or GLYC more profitable? Galectin Therapeutics' return on equity of 0.00% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% GlycoMimetics N/A -160.93%-132.85% Do analysts rate GALT or GLYC? Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 900.00%. GlycoMimetics has a consensus target price of $8.00, suggesting a potential upside of 3,116.73%. Given GlycoMimetics' higher probable upside, analysts plainly believe GlycoMimetics is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryGlycoMimetics beats Galectin Therapeutics on 8 of the 12 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.>> Register for the Workshop Now Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.04M$6.58B$5.16B$9.02BDividend YieldN/A2.96%4.96%4.19%P/E RatioN/A10.6486.5417.06Price / Sales1,603.72195.851,126.05116.49Price / CashN/A57.1543.2737.84Price / Book0.415.124.824.96Net Income-$36.90M$150.98M$120.07M$225.17M7 Day Performance14.87%1.72%1.23%4.45%1 Month Performance-28.31%-5.99%16.54%3.07%1 Year Performance-89.46%6.01%28.85%17.61% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics4.409 of 5 stars$0.25+5.2%$8.00+3,116.7%-90.0%$16.04M$10,000.000.0050Short Interest ↓Gap UpGALTGalectin Therapeutics1.6825 of 5 stars$0.89-14.4%$11.00+1,136.0%-30.7%$55.86MN/A-1.229Analyst ForecastShort Interest ↑Gap DownHigh Trading VolumeMURAMural Oncology3.5847 of 5 stars$3.27+2.8%$16.00+389.3%-45.6%$55.66MN/A-0.36119CNTBConnect Biopharma2.8723 of 5 stars$1.01+5.7%$8.00+696.0%-3.4%$55.53M$24.12M0.00110Short Interest ↑Gap DownIOBTIO Biotech3.2378 of 5 stars$0.84+8.9%$9.33+1,011.1%-47.9%$55.34MN/A-0.6130IVVDInvivyd3.8413 of 5 stars$0.45+1.1%$7.89+1,657.5%-87.1%$53.68M$11.56M-0.23100Short Interest ↓Gap UpDYAIDyadic International3.0606 of 5 stars$1.81+3.4%$6.00+231.5%+21.7%$53.56M$3.36M-7.877Short Interest ↓Gap UpSTTKShattuck Labs3.2108 of 5 stars$1.09-5.2%$8.67+695.1%-82.6%$52.04M$6.44M-0.71100Gap UpALVRAlloVir2.7349 of 5 stars$0.45+11.4%N/A-32.8%$52.01MN/A-0.51110Short Interest ↓News CoveragePositive NewsGap DownSPROSpero Therapeutics4.5951 of 5 stars$0.94-1.6%$5.00+431.9%-29.9%$51.25M$89.87M13.4346CELUCelularity1.8181 of 5 stars$2.31-0.9%N/A-9.5%$50.79M$48.20M0.00220Short Interest ↓Positive NewsGap Down Related Companies and Tools Related Companies Galectin Therapeutics Alternatives Mural Oncology Alternatives Connect Biopharma Alternatives IO Biotech Alternatives Invivyd Alternatives Dyadic International Alternatives Shattuck Labs Alternatives AlloVir Alternatives Spero Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLYC) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
